Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Survival factor NFIL3 restricts FOXO-induced gene expression in cancer.

Keniry M, Pires MM, Mense S, Lefebvre C, Gan B, Justiano K, Lau YK, Hopkins B, Hodakoski C, Koujak S, Toole J, Fenton F, Calahan A, Califano A, DePinho RA, Maurer M, Parsons R.

Genes Dev. 2013 Apr 15;27(8):916-27. doi: 10.1101/gad.214049.113.

2.

Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Shen-Li H, Koujak S, Szablocs M, Parsons R.

Cancer Biol Ther. 2010 Dec 1;10(11):1194-200. Epub 2010 Dec 1.

3.

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.

4.

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.

Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H, Parsons R.

Science. 2009 Sep 4;325(5945):1261-5. doi: 10.1126/science.1173569.

5.

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R.

Cancer Res. 2009 Aug 1;69(15):6299-306. doi: 10.1158/0008-5472.CAN-09-0820. Epub 2009 Jul 14.

6.

Irs2 inactivation suppresses tumor progression in Pten+/- mice.

Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, Schiff SC, Davidian G, Licata S, Gruvberger-Saal S, Murty VV, Nandula S, Efstratiadis A, Kushner JA, White MF, Parsons R.

Am J Pathol. 2009 Jan;174(1):276-86. doi: 10.2353/ajpath.2009.080086. Epub 2008 Dec 18.

7.

PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer.

Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, Hibshoosh H, Tycko B, Parsons R.

Oncogene. 2008 Aug 7;27(34):4657-65. doi: 10.1038/onc.2008.101. Epub 2008 Apr 14.

8.

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A.

Nat Genet. 2008 Jan;40(1):102-7. Epub 2007 Dec 9.

9.

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9. Epub 2007 Apr 23.

Supplemental Content

Loading ...
Support Center